30mgPurity Exceeds 99%
Tirzepatide 30mg
Tirzepatide (LY3298176)
Tirzepatide is a dual GIP and GLP-1 receptor agonist. The 30mg variant provides extended supply for comprehensive research protocols requiring sustained dual-receptor investigation.
For Research Use Only
Not for human consumption, veterinary use, or any therapeutic applications.
Purity
Purity Exceeds 99%
Storage
36-46°F (2-8°C)
Origin
Made in USA
Documentation
COA Available
Procurement Information
This product is available exclusively to qualified research institutions and licensed facilities through authorized distribution channels.
- Valid research credentials required
- Orders processed through authorized agents only
- End-user certification documentation required
Research Mechanisms
- Dual receptor agonist (GLP-1 and GIP)
- Multi-pathway energy regulation
- Research into insulin sensitivity mechanisms
- Glucose-dependent insulinotropic effects
- Appetite regulation via complementary receptor pathways
Research Background
- FDA approved as Mounjaro for type 2 diabetes (2022)
- SURMOUNT clinical trial series for weight management
- Studies showing superior body weight reduction vs. GLP-1 monotherapy
- Research into cardiovascular and hepatic benefits
Storage & Handling
Recommended Storage Conditions
Store at 36–46°F (2–8°C). Protect from light. Do not freeze.
- - Keep away from direct sunlight
- - Maintain consistent temperature
- - Check expiration date before use
- - Reconstituted peptides: use within 28 days